AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
Business & Industry
- Amgen and Adaptive Biotechnologies announce strategic partnership to develop a therapeutic to prevent or treat COVID-19
- First patient outside U.S. treated in global Kevzara® (sarilumab) clinical trial program for patients with severe COVID-19
- Consignment of 30 million hydroxychloroquine tablets ships to US Department of Health and Human Services
- Novartis and life sciences companies commit expertise and assets to the fight against COVID-19 pandemic alongside Bill & Melinda Gates Foundation
- Amgen and the Amgen Foundation commit up to $12.5 million to support COVID-19 relief efforts
Research & Development
- Possible coronavirus drug identified by Australian scientists
- Clues to COVID-19 coronavirus's vulnerability emerge from an antibody against SARS
- New guidelines on caring for ICU patients with COVID-19
- FDA approves first plasma therapy for Houston Methodist COVID-19 patient
- Experimental AI tool predicts which COVID-19 patients develop respiratory disease
- Nafamostat is expected to prevent the transmission of new coronavirus infection (COVID-19)
- Singapore modelling study estimates impact of physical distancing on reducing spread of COVID-19
Conferences & Events
- Pre-Filled Syringes West Coast 2021
- Pre-Filled Syringes East Coast Conference 2020
- SMi's 4th Annual Pharmaceutical Microbiology West Coast
- SMi's 20th Annual Pain Therapeutics Conference 2020
- SMi's 3rd Annual Pharmaceutical Microbiology East Coast
- SMi's 22nd Annual Superbugs & Superdrugs Conference 2020
- SMi Presents the 3rd Annual Conference: Injectable Drug Delivery 2020
Regulatory Affairs
- FDA Coordinates National Effort to Develop Blood-Related Therapies for COVID-19
- FDA Continues to Accelerate Development of Novel Therapies for COVID-19
- The FDA is facilitating access to convalescent plasma collected from recovered COVID-19 patients
- FDA continues to facilitate development of COVID-19 treatments
- FDA and FTC warn seven companies selling fraudulent products that claim to treat or prevent COVID-19